Tandem Diabetes Care, Inc.
TNDM
Rank in Stocks
#7281
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating,... Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Share Price
$20.07
Last synced: 2026-11-13
Market Cap
$1.40B
Change (1 day)
14.62%
Change (1 year)
7.85%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Tandem Diabetes Care, Inc. (TNDM)
Category
Healthcare
EPS for Tandem Diabetes Care, Inc. (TNDM)
EPS as of September 2026 TTM: $-0.72
According to Tandem Diabetes Care, Inc.'s latest financial reports, its current EPS (TTM) is $-0.72. At the end of 2025 the company had an EPS of $-3.04, a decrease compared to its 2024 EPS of $-1.47.
EPS history for Tandem Diabetes Care, Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.72 | -76.32% |
| 2025 | $-3.04 | 106.80% |
| 2024 | $-1.47 | -57.14% |
| 2023 | $-3.43 | 133.33% |
| 2022 | $-1.47 | -688.00% |
| 2021 | $0.25 | -144.64% |
| 2020 | $-0.56 | 33.33% |
| 2019 | $-0.42 | -83.53% |
| 2018 | $-2.55 | -80.17% |
| 2017 | $-12.86 | -52.89% |
| 2016 | $-27.30 | 9.03% |
| 2015 | $-25.04 | -26.72% |
| 2014 | $-34.17 | 24.12% |
| 2013 | $-27.53 | 4.60% |
| 2012 | $-26.32 | 29.40% |
| 2011 | $-20.34 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $2.70 | -475.00% |
US
|
|
| $4.09 | -668.06% |
IE
|
|
| $9.45 | -1,412.50% |
US
|
|
| $2.37 | -429.17% |
US
|
|
| $1.77 | -345.83% |
US
|
Questions about Tandem Diabetes Care, Inc.'s earnings per share (EPS)
What is Tandem Diabetes Care, Inc.'s earnings per share (EPS)?
Tandem Diabetes Care, Inc.'s earnings per share (EPS) over the last twelve months is $-0.72, as of Sep 2026.
What was Tandem Diabetes Care, Inc.'s earnings per share (EPS) in 2025?
In 2025, Tandem Diabetes Care, Inc.'s earnings per share (EPS) was $-3.04, compared with $-1.47 in 2024.
How has Tandem Diabetes Care, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Tandem Diabetes Care, Inc.'s earnings per share (EPS) was highest in 2021 ($0.25) and lowest in 2023 ($-3.43).
How does Tandem Diabetes Care, Inc.'s earnings per share (EPS) compare with similar companies?
Tandem Diabetes Care, Inc.'s earnings per share (EPS) ($-0.72) is lower than that of all 5 similar companies listed above. The highest among them is Stryker Corporation, with $9.45.